SCHEMBL5558730

SCHEMBL5558730

COc1ccc(-c2cccc(C#N)c2)cn1

nearest known ligand 0.60

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HSD17B1 P14061 2/20 0.60
HSD17B2 P37059 2/20 0.60
GABRG2 P18507 3/20 0.52
GABRB3 P28472 3/20 0.52
GABRA5 P31644 3/20 0.52
GABRA3 P34903 3/20 0.52
KIT P10721 1/20 0.50
CLK4 Q9HAZ1 2/20 0.49
NPY5R Q15761 1/20 0.48
ADORA2A P29274 1/20 0.47
ADORA1 P30542 1/20 0.47
SCN9A Q15858 1/20 0.46
EGLN1 Q9GZT9 1/20 0.46
CYP2A6 P11509 1/20 0.45
USP30 Q70CQ3 1/20 0.45
CYP1A2 P05177 2/20 0.45
CYP3A4 P08684 2/20 0.45
ALDH1A1 P00352 1/20 0.45
MAP4K4 O95819 1/20 0.45
GABRA1 P14867 1/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3266198 0.80 CLK4 (0.53) GABRG2GABRB3GABRA5GABRA3CLK4
SCHEMBL13575381 0.78 HSD17B1 (0.67) HSD17B1HSD17B2KITADORA2AADORA1
SCHEMBL12498936 0.78 HSD17B1 (0.67) HSD17B1HSD17B2KITADORA2AADORA1
SCHEMBL13575386 0.78 HSD17B1 (0.67) HSD17B1HSD17B2CLK4ADORA2AADORA1
SCHEMBL15577625 0.77 KIT (0.57) GABRG2GABRB3GABRA5GABRA3KIT
SCHEMBL17672770 0.77 SCN9A (0.49) HSD17B1HSD17B2KITSCN9ACYP2A6
SCHEMBL17547019 0.76 HSD17B1 (0.65) HSD17B1HSD17B2ADORA2AADORA1CYP2A6
SCHEMBL13575397 0.76 HSD17B1 (0.65) HSD17B1HSD17B2ADORA2AADORA1CYP2A6
SCHEMBL5562910 0.76 MAP4K4 (0.62) GABRG2GABRB3GABRA5GABRA3CLK4
SCHEMBL4021783 0.76 CYP11B2 (0.56) GABRG2GABRB3GABRA5GABRA3CLK4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1474416-B1 DIHYDROBENZODIAZEPIN-2-ONE-DERIVATIVES FOR THE TREATMENT OF NEUROLOGICAL DISORDERS HOFFMANN LA ROCHE (CH) 2007-09-26 EP disclosed
US-6949542-B2 Dihydro-benzo[b][1,4]diazepin-2-one derivatives HOFFMAN-LA ROCHE INC. (US) 2005-09-27 US disclosed
EP-1474416-A1 DIHYDROBENZODIAZEPIN-2-ONE-DERIVATIVES FOR THE TREATMENT OF NEUROLOGICAL DISORDERS F. HOFFMANN-LA ROCHE AG (CH) 2004-11-10 EP disclosed
US-20030166639-A1 Dihydro-benzo[b][1,4]diazepin-2-one derivatives F. HOFFMAN-LA ROCHE AG (CH) 2003-09-04 US disclosed
WO-2003066623-A1 DIHYDROBENZODIAZEPIN-2-ONE DERIVATIVES FOR THE TREATMENT OF NEUROLOGICAL DISORDERS F. HOFFMANN-LA ROCHE AG (CH) 2003-08-14 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030166639-A1 Dihydro-benzo[b][1,4]diazepin-2-one derivatives CYP1B1, GRIN2B, CYP4B1 HSD17B1 399/4885HSD17B2 523/4885GABRG2 268/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.